BrightGene looks to the West as obesity shot nears China approvalnews2026-07-02T10:48:43+00:00July 2nd, 2026|Endpoints News|
Oura inks partnership with Eli Lilly’s prescription platformnews2026-06-23T13:00:50+00:00June 23rd, 2026|Endpoints News|
UK waitlist for Novo’s Wegovy pill triples in week after approval, major online pharmacy saysnews2026-06-17T15:43:57+00:00June 17th, 2026|Endpoints News|
Sciwind has two Western partners for its obesity drug, but is open to morenews2026-06-12T09:00:41+00:00June 12th, 2026|Endpoints News|
#ADA26: AstraZeneca GLP-1 pill cuts weight 10.5% after six monthsnews2026-06-08T20:15:05+00:00June 8th, 2026|Endpoints News|
#ADA26: Novo Nordisk targets 2030 launch for triple-G obesity shotnews2026-06-08T13:17:32+00:00June 8th, 2026|Endpoints News|
#ADA26: 19% of Phase 3 patients quit Boehringer obesity shot over side effectsnews2026-06-07T18:30:38+00:00June 7th, 2026|Endpoints News|
Lilly obesity meds Foundayo and Zepbound to gain CVS coveragenews2026-05-28T17:28:36+00:00May 28th, 2026|Endpoints News|
Lilly points to low-dose Zepbound and Foundayo as weight loss maintenance optionsnews2026-05-12T22:01:09+00:00May 12th, 2026|Endpoints News|
Court dismisses part of Lilly lawsuit against Empower, some claims can proceednews2026-04-30T18:16:20+00:00April 30th, 2026|Endpoints News|
